Navigation Links
Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55
Date:10/26/2011

months ended September 30, 2010, the if-converted method is anti-dilutive; therefore, the preferred stock conversion is excluded from the computation of diluted earnings per share.Mylan Inc. and SubsidiariesCondensed Consolidated Balance Sheets(Unaudited; in thousands)September 30, 2011December 31, 2010Assets:   Current assets:Cash and cash equivalents

$
512,837$
2,052Restricted cash

9,32923,972Marketable securities

30,24929,085Accounts receivable, net

1,280,0121,157,081Inventories

1,386,5411,240,271Other current assets

390,070446,982Total current assets

3,609,0383,559,443   Intangible assets, net

2,226,2832,501,150   Goodwill

3,558,6773,599,334   Other non-current assets

1,724,1201,876,877Total assets

$
,118,118$
,536,804Liabilities:   Current liabilities

$
2,374,934$
,809,612   Long-term debt (b)

4,483,2215,263,376   Other non-current liabilities

765,827848,415Total liabilities

7,623,9827,921,403Noncontrolling interest

12,58013,522Mylan Inc. shareholders' equity

3,481,5563,601,879Total liabilities and equity

$
,118,118$
,536,804(b) At September 30, 2011, long-term debt of approximately $680.3 million related to the Senior Convertible Notes and a portion of the Euro Tranche A and B Term Loans is now classified as a current liability.Mylan Inc. and SubsidiariesSummary of Revenues by Segment(Unaudited; in millions)Three Months EndedNine Months EndedSeptember 30,September 30, 2011201020112010Generics:Third party net salesNorth America

$
97.0$
572.5$ 2,120.3$ 1,713.8EMEA

350.8363.51,118.61,148.9Asia Pacific

310.6267.9897.6769.1Total third party net sales

1,358.41,203.94,136.53,631.8Other third party revenues

3.19.316.831.9Total third party revenues

1,361.51,213.24,153.33,663.7Intersegment revenues

0.42.41.234.3Generics total revenue
'/>"/>

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Sangamo BioSciences Reports Third Quarter 2011 Financial Results
2. Life Technologies Announces Third Quarter 2011 Results
3. Insmed to Host 2011 Third Quarter Earnings Conference Call
4. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
5. Anthera Announces Third Quarter 2011 Financial Report and Conference Call
6. Pacira Pharmaceuticals, Inc. Announces Timing for Third Quarter 2011 Financial Results Webcast and Conference Call
7. Amgen’s Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40
8. HeartWare Schedules Third Quarter Conference Call and Webcast
9. Dyadic International Announces Date and Time of Third Quarter 2011 Financial Results Release and Conference Call
10. United Therapeutics Corporation to Announce Third Quarter 2011 Financial Results Before Market Open on Thursday, October 27, 2011
11. Sangamo BioSciences Announces Third Quarter 2011 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... July 29, 2015 US-Australian drug discovery company, ... confirmed it is committed to progressing its ground-breaking technology ... practicable and to ensure the Company delivers the best ... Iain Ross , said the Company currently had ... pre-clinical programs, discovery programs and academic partnerships and initiatives, ...
(Date:7/29/2015)...  HealthSouth Corporation (NYSE: HLS ), one ... services, offering both facility-based and home-based post-acute services, ... second quarter ended June 30, 2015. ... growth in both segments and an 11.0% increase ... and Chief Executive Officer of HealthSouth. "While reported ...
(Date:7/29/2015)... , July 29, 2015 ... announced the addition of the "Global Biosimilars ... offering. The Global Biosimilars Market, 2015 ... the rapidly growing biosimilars market. With the blockbuster ... to minimize costs, biosimilars are being viewed as ...
(Date:7/29/2015)... 2015  Therapath Neuropathology ( www.Therapath.com ), a ... VA and Military Medical centers both domestically and ... and Sweat Gland Nerve Fiber Density (SGNFD) for ... ). Demonstration of a reduction ... punch skin biopsy is a highly sensitive and ...
Breaking Biology Technology:Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15HealthSouth Reports Results for Second Quarter 2015 16HealthSouth Reports Results for Second Quarter 2015 17HealthSouth Reports Results for Second Quarter 2015 18HealthSouth Reports Results for Second Quarter 2015 19HealthSouth Reports Results for Second Quarter 2015 20HealthSouth Reports Results for Second Quarter 2015 21HealthSouth Reports Results for Second Quarter 2015 22HealthSouth Reports Results for Second Quarter 2015 23HealthSouth Reports Results for Second Quarter 2015 24HealthSouth Reports Results for Second Quarter 2015 25HealthSouth Reports Results for Second Quarter 2015 26HealthSouth Reports Results for Second Quarter 2015 27
... provide a,sensitive method to detect protease activity, measure ... of drug candidates. LI-COR,Biosciences now offers three different ... BACE, and IRDye 800CW/QC-1 CSP-3., "These substrates ... conjugated dye by our novel IRDye QC-1 quencher," ...
... Studies show that up to 30% of coffees ordered as ,decaf, ... ... Ever wonder whether the,coffee you had after dinner was really decaf? ... caffeine test strip from,Silver Lake Research, the leader in at-home water quality ...
... today that Gemstone Acquisition Corporation, a wholly-owned,subsidiary of ... purchase all,outstanding shares of common stock of Genelabs ... interest and less any required withholding,taxes. The tender ... announced,Agreement and Plan of Merger dated October 29, ...
Cached Biology Technology:LI-COR Introduces Three IRDye(R) Near-Infrared Fluorescence Resonance Energy Transfer (NIR-FRET) Protease Substrates 2Is Your Decaf Really Decaf? 2GlaxoSmithKline Commences Tender Offer to Acquire Genelabs Technologies, Inc. 2GlaxoSmithKline Commences Tender Offer to Acquire Genelabs Technologies, Inc. 3
(Date:7/30/2015)... July 30, 2015 Cellecta, Inc., a ... function analysis and biomarker discovery, announced the release ... Library targeting all human protein coding genes. CRISPR ... out" a gene,s function. Cellecta,s new Human Whole ... screening tool so that researchers can investigate in ...
(Date:7/23/2015)... , July 23, 2015 Research ... addition of the "Global Outlook of the ... offering. The global biometrics market ... public and commercial applications owing to the uptake ... witness a transformation that enhances the growth of ...
(Date:7/20/2015)... 2015  Acuity Market Intelligence,s latest research "The ... Commerce and Privacy" forecasts that between 2014 and ... be downloaded to smart mobile devices by 2.2 ... is projected to generate more than $67.9 billion ... forecast period.    "Biometrics is at ...
Breaking Biology News(10 mins):CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2
... molecular mechanism in the liver that explains, for the ... and trans-fatty acids causes elevated blood levels of cholesterol ... and certain cancers. , In the Jan. 28 issue ... that the harmful effects of saturated and trans fats ...
... treated with radical mastectomy and adjuvant chemotherapy, the addition ... few long-term toxic effects, according to a 20-year follow-up ... 19 issue of the Journal of the National Cancer ... was designed to determine the effect on survival of ...
... a recent U.S. study, investigators in Japan found no ... form of high blood pressure, as reported in the ... now available online. , The researchers reported that they ... also known as the Kaposi's sarcoma virus, in the ...
Cached Biology News:Scientists ID molecular 'switch' in liver that triggers harmful effects of saturated and trans fats 2Scientists ID molecular 'switch' in liver that triggers harmful effects of saturated and trans fats 3Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down 2Association of herpesvirus with lung disorder questioned 2
... leading provider of X-ray crystallography services ... screening services to its pharmaceutical and ... binding of drug-like fragments to the ... targets, allowing scientists to develop novel, ...
...
... acetylcholinesterase (AChE) activity. This is a highly ... non-radioactive and easy to use assay for ... acetylcholine. A series of coupled enzyme reactions ... a change in luminescence. Inhibitors of AChE ...
Rabbit polyclonal to Vitronectin ( Abpromise for all tested applications). Antigen: Full length native Vitronectin (Cow) Entrez Gene ID: 7448 Swiss Protein ID: P04004...
Biology Products: